Recent Securities Litigations

ACADIA Pharmaceuticals Inc. Common Stock (NASDAQ: ACAD)

Company Name:ACADIA Pharmaceuticals Inc. Common Stock
Stock Symbol:NASDAQ: ACAD
Class Period Start:06/15/2020
Class Period End (inclusive):04/04/2021

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.